Mereo BioPharma Group plc Files 8-K for Material Agreement
Ticker: MREO · Form: 8-K · Filed: Apr 15, 2024 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 8-K |
| Filed Date | Apr 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-K
TL;DR
Mereo BioPharma just signed a big deal, filing an 8-K to let everyone know.
AI Summary
On April 15, 2024, Mereo BioPharma Group plc entered into a material definitive agreement. The company, incorporated in England and Wales with its principal executive offices in London, filed this 8-K report to disclose this significant event. No specific details regarding the agreement or financial implications were provided in the excerpt.
Why It Matters
This filing indicates a significant development for Mereo BioPharma Group plc, potentially impacting its business operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The filing of an 8-K for a material definitive agreement suggests a significant event that could introduce new risks or opportunities for the company.
Key Players & Entities
- Mereo BioPharma Group plc (company) — Registrant
- April 15, 2024 (date) — Date of earliest event reported
- England and Wales (jurisdiction) — State or other jurisdiction of incorporation
- London (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Mereo BioPharma Group plc?
The provided excerpt does not specify the nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on April 15, 2024.
Where are Mereo BioPharma Group plc's principal executive offices located?
Mereo BioPharma Group plc's principal executive offices are located at Fourth Floor, One Cavendish Place, London, W1G 0QF, United Kingdom.
What is the company's state of incorporation?
The company is incorporated in England and Wales.
What is the SEC file number for Mereo BioPharma Group plc?
The SEC file number for Mereo BioPharma Group plc is 001-38452.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-04-15 07:30:34
Filing Documents
- d818381d8k.htm (8-K) — 28KB
- d818381dex101.htm (EX-10.1) — 10KB
- g818381g87d27.jpg (GRAPHIC) — 10KB
- 0001193125-24-095508.txt ( ) — 220KB
- mreo-20240415.xsd (EX-101.SCH) — 3KB
- mreo-20240415_def.xml (EX-101.DEF) — 15KB
- mreo-20240415_lab.xml (EX-101.LAB) — 24KB
- mreo-20240415_pre.xml (EX-101.PRE) — 16KB
- d818381d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 10.1 Extension Letter to the Cooperation Agreement between the Company and Rubric Capital, dated April 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. MEREO BIOPHARMA GROUP PLC Date: April 15, 2024 By: /s/ Charles Sermon Name: Charles Sermon Title: General Counsel